Soligenix granted Hong Kong patent for production of synthetic hypericin

Soligenix (SNGX) announced that the Hong Kong Patent Office has granted the patent entitled “Systems and Methods for Producing Synthetic Hypericin”. The newly issued patent’s claims are directed to a novel, highly purified form of synthetic hypericin manufactured through a unique proprietary process. Synthetic hypericin is the active pharmaceutical ingredient in HyBryte, the company’s photodynamic therapy for the treatment of cutaneous T-cell lymphoma, set to initiate a confirmatory Phase 3 clinical trial before the end of the year. The same active ingredient is also used in SGX302, a potential topical treatment for plaque psoriasis. This new granted patent is a related patent to one previously issued in the U.S., and is in the same family as another patent granted in Europe. These patents are expected to expire in 2036.